What Researchers Did
Researchers conducted a prospective study on 44 patients with pelvic radiation disease (PRD) who had not responded to standard treatments, evaluating the effectiveness of hyperbaric oxygen therapy (HBOT).
What They Found
The SOMA-LENT score, a measure of radiation injury, significantly decreased in 59% of patients. Specific symptoms such as tenesmus (P = 0.02), bleeding (P = 0.0001), and ulceration (P = 0.001) also significantly improved after HBOT. Furthermore, 33% of patients with colostomies (4 out of 12) were able to have them closed.
What This Means for Canadian Patients
Canadian patients experiencing pelvic radiation disease (PRD) resistant to conventional treatments may find hyperbaric oxygen therapy (HBOT) to be a beneficial option. This therapy could potentially alleviate severe symptoms like bleeding, tenesmus, and ulceration, and in some cases, allow for colostomy closure, enhancing their quality of life.
Canadian Relevance
This study was not conducted in Canada, nor does it feature Canadian authors. However, pelvic radiation disease is a known complication of cancer treatment in Canada, and HBOT for radiation tissue damage is a recognized application in some contexts.
Study Limitations
A key limitation of this study is the absence of a control group, which makes it difficult to isolate the exact impact of HBOT.